Penn Pharma, a provider of integrated drug-development, clinical-trial supply, and manufacturing services, has partnered with GEA Pharma Systems to open a new facility for the development and manufacture of oncology drugs. The company invested for £14 million ($19 million), built a high-containment manufacturing plant for the production of multiple APIs in batches of 1–120 kg.
The new 15,000 ft2 site offers a geometrically scalable dispensing, granulation, and blending process from powder to capsules. Highly contained equipment trains were designed to minimize the need for personal protective equipment and reduce the use of isolators to a minimum.
Source: GEA Pharma Systems